Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era.
作者信息
Cheung Kevin J, Davidson Nancy E
机构信息
Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA.
出版信息
J Natl Cancer Inst. 2019 Jul 1;111(7):641-643. doi: 10.1093/jnci/djy203.
Abstract
摘要
相似文献
1
Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era.双重麻烦：现代对侧乳腺癌的风险管理
J Natl Cancer Inst. 2019 Jul 1;111(7):641-643. doi: 10.1093/jnci/djy203.
2
Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.美国女性 1992-2016 年期间，基于首次乳腺癌特征的对侧乳腺癌风险。
Breast Cancer Res. 2021 Feb 17;23(1):24. doi: 10.1186/s13058-021-01400-3.
3
Minimal impact of postmastectomy radiation therapy on locoregional recurrence for breast cancer patients with 1 to 3 positive lymph nodes in the modern treatment era.在现代治疗时代，乳房切除术后放疗对1至3个阳性淋巴结的乳腺癌患者局部区域复发的影响极小。
Surg Oncol. 2017 Jun;26(2):163-170. doi: 10.1016/j.suronc.2017.03.003. Epub 2017 Mar 16.
4
[Preventive surgical prcedures for inherited risk of breast cancer].[针对遗传性乳腺癌风险的预防性外科手术]
Ned Tijdschr Geneeskd. 2005 Nov 26;149(48):2663-7.
5
The impact of the Biomolecular Era on breast cancer surgery.生物分子时代对乳腺癌手术的影响。
Surgeon. 2017 Jun;15(3):169-181. doi: 10.1016/j.surge.2016.09.007. Epub 2016 Nov 2.
6
Routine contralateral breast biopsy: helpful or irrelevant? Experience in 871 patients, 1979-1993.常规对侧乳房活检：有益还是无关？1979年至1993年871例患者的经验
Ann Surg. 1997 Apr;225(4):370-6. doi: 10.1097/00000658-199704000-00005.
7
Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment.T1、2 期乳腺癌伴 1-3 个阳性淋巴结患者行乳房切除术和全身治疗后的局部区域复发风险。
Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):392-8. doi: 10.1016/j.ijrobp.2014.02.013. Epub 2014 Apr 7.
8
ASO Author Reflections: Surgical De-escalation for the Management of Ipsilateral Breast Cancer Recurrence in the Modern Era of Multimodality Treatment.美国骨科学会作者反思：在多模式治疗的现代时代，手术降级用于同侧乳腺癌复发的管理。
Ann Surg Oncol. 2022 Oct;29(10):6454-6455. doi: 10.1245/s10434-022-12310-9. Epub 2022 Jul 29.
9
Regional Nodal Irradiation in the Modern Era of Breast Cancer Management.
Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):241-243. doi: 10.1016/j.ijrobp.2017.10.036.
10
Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk.家族性和对侧乳腺癌风险相互作用，导致高风险。
Cancer Res. 2007 Feb 1;67(3):868-70. doi: 10.1158/0008-5472.CAN-06-3854.
引用本文的文献
1
Comparing Local and Systemic Control between Partial- and Whole-Breast Radiotherapy in Low-Risk Breast Cancer-A Meta-Analysis of Randomized Trials.低危乳腺癌局部与全乳放疗的局部和全身控制比较——随机试验的荟萃分析
Cancers (Basel). 2021 Jun 13;13(12):2967. doi: 10.3390/cancers13122967.
本文引用的文献
1
The Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype.辅助全身治疗方案对对侧乳腺癌风险和受体亚型的影响。
J Natl Cancer Inst. 2019 Jul 1;111(7):709-718. doi: 10.1093/jnci/djz010.
2
Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq.通过单细胞 RNA 测序揭示三阴性乳腺癌中的亚克隆异质性和侵袭性疾病状态。
Nat Commun. 2018 Sep 4;9(1):3588. doi: 10.1038/s41467-018-06052-0.
3
Single-Cell Transcriptomes Distinguish Stem Cell State Changes and Lineage Specification Programs in Early Mammary Gland Development.单细胞转录组图谱解析早期乳腺发育过程中干细胞状态转变和谱系特化程序
Cell Rep. 2018 Aug 7;24(6):1653-1666.e7. doi: 10.1016/j.celrep.2018.07.025.
4
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.基于 21 基因表达检测的乳腺癌辅助化疗。
N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.
5
Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity.单细胞 RNA 测序鉴定人乳腺上皮细胞的特征，确定细胞多样性。
Nat Commun. 2018 May 23;9(1):2028. doi: 10.1038/s41467-018-04334-1.
6
Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.乳腺癌家族史与年轻女性对侧乳腺癌风险：来自妇女环境癌症和辐射流行病学研究的最新进展。
J Clin Oncol. 2018 May 20;36(15):1513-1520. doi: 10.1200/JCO.2017.77.3424. Epub 2018 Apr 5.
7
Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).早期乳腺癌中的蒽环类药物：ABC试验——USOR 06 - 090、NSABP B - 46 - I/USOR 07132以及NSABP B - 49（NRG肿瘤学研究组）
J Clin Oncol. 2017 Aug 10;35(23):2647-2655. doi: 10.1200/JCO.2016.71.4147. Epub 2017 Apr 11.
8
Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.在一般社区环境下，辅助他莫昔芬和芳香酶抑制剂治疗与美国乳腺癌女性对侧乳腺癌风险的关系。
JAMA Oncol. 2017 Feb 9;3(2):186-193. doi: 10.1001/jamaoncol.2016.3340. Epub 2016 Oct 6.
9
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.70 基因特征作为早期乳腺癌治疗决策的辅助手段。
N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.
10
Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study.WECARE研究中乳腺癌的全身治疗与后续对侧乳腺癌风险
Breast Cancer Res. 2016 Jul 12;18(1):65. doi: 10.1186/s13058-016-0726-0.
Zotero 插件